In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?
Simultaneous administration of zidovudine, acriflavine and celliptium to Friend virus-injected mice eradicates the virus, as evidenced by the impossibility of the treated-mouse serum, when injected to virgin recipients, to induce spleen foci formation. An adapted preliminary protocol given to patients in whose p 24 antigen was present in the blood, lead to a considerable reduction of that marker. The cures lasted 3 weeks, and were repeated after 3-week intervals. Since p 24 antigen returns to pre-treatment levels at the end of the interval, research should concentrate on the maintenance of the effect during the interval.
Mathé
G
G
Institut de Cancérologie et d'Immunologie Hôpital Suisse de Paris, France.
Pontiggia
P
P
Bourut
C
C
Chenu
E
E
Orbach-Arbouys
S
S
D000386:AIDS-Related Complex / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000167:Acriflavine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004359:Drug Therapy, Combination; D004611:Ellipticines / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005622:Friend murine leukemia virus / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D015215:Zidovudine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D004611:Ellipticines; D000167:Acriflavine; D015215:Zidovudine